Results 111 to 120 of about 11,830 (209)

Thiopurines

, 2015
promotiedatum: 4-12-2015 prom-id ...
openaire   +2 more sources

XDH 유전자형과 한국인 크론병환자에서 thiopurine 치료 중 발생한 골수억제와의 관련성에 대한 유전자 연관분석

, 2015
배경: Thiopurine 계 약제인 azathioprine (AZA)/6-mercaptopurine (6-MP) 는 염증성장질환의 치료제로 흔히 사용되며 부작용으로 백혈구감소증이 있다. Thiopurine 의 대사에 관련하는 thiopurine S-methyltransferase (TPMT) 의 활성도의 차이에 의해서 thiopurine 의 독성의 개인차가 초래되며 TPMT 활성도는 TPMT 유전자의 다형성과 연관되어있음이 잘 알려져 있으나 염증성 ...
박수경
core  

The fate of thiopurine metabolites after switching to low-dose thiopurine with allopurinol or thioguanine in IBD patients:A retrospective analysis

Aims: Shunting (hypermethylating) thiopurine metabolism, characterized by excessive 6-MMPR production and (sub)therapeutic 6-TGN levels, poses a significant challenge in the treatment of inflammatory bowel disease (IBD).
Mulder, Chris J. J., Bayoumy, Ahmed B., D'Agnolo, Hedwig M. A., Derijks, Luc J. J., de Boer, Nanne K. H.   +4 more
core   +1 more source

A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden. [PDF]

Cancer Res Commun
Secher CF, Højgaard M, Spanggaard I, Schmidt AY, Guo Y, Robinson L, De Zio D, Toksvang LN, Bagger FO, Schmiegelow K, Rohrberg KS.   +10 more
europepmc   +1 more source

Pharmacogenetic Risk Factors for Thiopurine-Induced Leukopenia in Patients with Inflammatory Bowel Disease. [PDF]

Yonsei Med J
Boo EK, Yu J, Oh S, Cheon JH, Kim JH.
europepmc   +1 more source

Development and Validation of Simultaneous Quantification of 6TGN and 6MMPN in Whole Blood Using LC-MS/MS: An Application to Therapeutic Drug Monitoring in Hematological Malignancies and in Inflammatory Bowel Diseases. [PDF]

Biomed Chromatogr
Allard M, Vignal N, Loiseau A, Sauvageon H, Médard Y, Plé A, Jacqz-Aigrain E, Mourah S, Goldwirt L.   +8 more
europepmc   +1 more source

PACSIN2 regulates mercaptopurine cytotoxicity and cellular biomechanics through Rac1 modulation in intestinal epithelial cells. [PDF]

Front Pharmacol
Norbedo A, Zudeh G, Fiducioso D, Senigagliesi B, Parisse P, Casalis L, Decorti G, Lucafò M, Stocco G.   +8 more
europepmc   +1 more source

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program. [PDF]

Ther Adv Gastroenterol
Rubin DT, Lees CW, Baert F, Kudela M, Bhattacharjee A, Lazin K, Goetsch M, Abbatemarco AM, Wosik K, Marshall JK.   +9 more
europepmc   +1 more source

Optimized thiopurine treatment in chronic inflammatory bowel disease.

, 2014
Thiopurines are effective in maintaining remission in chronic inflammatory bowel diseases, but incomplete response or side effects are common during standard-dose treatment. In this article thiopurine metabolism and pharmacogenetic aspects are summarized
Kiszka-Kanowitz, Marianne, Theede, Klaus, Nielsen, Anette Mertz   +2 more
core  

Pharmacogenetic Predictors of Chemotherapy Treatment-Related Toxicities in Paediatric and Adolescent Acute Lymphoblastic Leukemia: A Systematic Review, Meta-Analysis and Literature-Based Candidate Prioritization. [PDF]

Pharmaceuticals (Basel)
Chenchula S, Srinivasamurthy SK, Vincent V, Thakkar H, Ganguly S, Kayal S, Keerthivasagam S, Ramamoorthy J, Sharma S, Murugadoss K, Singh A, Pushpam D, Mathaiyan J, Jolly B, Scaria V, Gloor Y, Baleydier F, Bakhshi S, Dubashi B, Ansari M, Uppugunduri CRS.   +20 more
europepmc   +1 more source